Cited by 1,625COVID-19 Clinical Research StudiesRespiratory Support and MechanismsSARS-CoV-2 and COVID-19 Research

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

Open access

Geleris, Joshua, Sun, Yifei, Platt, Jonathan, Zucker, Jason, Baldwin, Matthew, Hripcsak, George, Labella, Angelena, Manson, Daniel K., Kubin, Christine, Barr, R. Graham, Sobieszczyk, Magdalena E., Schluger, Neil W.·2020·New England Journal of Medicine

DOI 10.1056/nejmoa2012410PMC PMC7224609

Open this paper in CoChat — free account

Abstract

BACKGROUND: Hydroxychloroquine has been widely administered to patients with Covid-19 without robust evidence supporting its use. METHODS: We examined the association between hydroxychloroquine use and intubation or death at a large medical center in New York City. Data were obtained regarding consecutive patients hospitalized with Covid-19, excluding those who were intubated, died, or discharged within 24 hours after presentation to the emergency department (study baseline). The primary end point was a composite of intubation or death in a time-to-event analysis. We compared outcomes in patients who received hydroxychloroquine with those in patients who did not, using a multivariable Cox model with inverse probability weighting according to the propensity score. RESULTS: Of 1446 consecutive patients, 70 patients were intubated, died, or discharged within 24 hours after presentation and were excluded from the analysis. Of the remaining 1376 patients, during a median follow-up of 22.5 days, 811 (58.9%) received hydroxychloroquine (600 mg twice on day 1, then 400 mg daily for a median of 5 days); 45.8% of the patients were treated within 24 hours after presentation to the emergency department, and 85.9% within 48 hours. Hydroxychloroquine-treated patients were more severely ill at baseline than those who did not receive hydroxychloroquine (median ratio of partial pressure of arterial oxygen to the fraction of inspired oxygen, 223 vs. 360). Overall, 346 patients (25.1%) had a primary end-point event (180 patients were intubated, of whom 66 subsequently died, and 166 died without intubation). In the main analysis, there was no significant association between hydroxychloroquine use and intubation or death (hazard ratio, 1.04, 95% confidence interval, 0.82 to 1.32). Results were similar in multiple sensitivity analyses. CONCLUSIONS: In this observational study involving patients with Covid-19 who had been admitted to the hospital, hydroxychloroquine administration was not associated with either a greatly lowered or an increased risk of the composite end point of intubation or death. Randomized, controlled trials of hydroxychloroquine in patients with Covid-19 are needed. (Funded by the National Institutes of Health.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa2012410

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
Gautret, P., Lagier, J., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Esteves-Vieira, V., et al. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105949 · Cited by 5,288
Retracted
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., Liu, X., Zhao, L. Y., Dong, E., Song, C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa237 · Cited by 2,696
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
Devaux, C. A., Rolain, J., Colson, P., & Raoult, D. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105938 · Cited by 1,122
Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial
Borba, M. G. S., Val, F. F. A., Sampaio, V. S., Alexandre, M. A. A., Melo, G. C., Brito, M., Mourão, M. P. G., Brito-Sousa, J. D., Baía-da-Silva, D., Guerra, M. V. F., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.8857 · Cited by 1,038
Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trialPreprint
Chen, Z., Hu, J., Zhang, Z., Jiang, S., Han, S., Yan, D., Zhuang, R., Hu, B., & Zhang, Z. (2020) · medRxiv · doi:10.1101/2020.03.22.20040758 · Cited by 861
[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].
Chen, J., Liu, D., Liu, L., Liu, P., Xu, Q., Xia, L., Ling, Y., Huang, D. F., Song, S., Zhang, D., et al. (2020) · PubMed Central · doi:10.3785/j.issn.1008-9292.2020.03.03 · Cited by 662
Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection
Fantini, J., Scala, C. D., Chahinian, H., & Yahi, N. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105960 · Cited by 566
Mechanism of action of hydroxychloroquine as an antirheumatic drug
Fox, R. I. (1993) · Seminars in Arthritis and Rheumatism · doi:10.1016/s0049-0172(10)80012-5 · Cited by 430
Design and Synthesis of Hydroxyferroquine Derivatives with Antimalarial and Antiviral Activities
Biot, C., Daher, W., Leleu‐Chavain, N., Fandeur, T., Khalife, J., Dive, D., & Clercq, E. D. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0601856 · Cited by 318

Show all 17 references

Sorted by citations

Items 701–800 of 1,000

Association between non-high-density lipoprotein to high-density lipoprotein ratio and reversion to normoglycemia in people with impaired fasting glucose: a 5-year retrospective cohort study
Mo, Z., Han, Y. Y., Cao, C., Huang, Q., Hu, Y., Yu, Z., & Hu, H. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01237-0 · Cited by 15
QT interval and arrhythmic safety of hydroxychloroquine monotherapy in coronavirus disease 2019
Sridhar, A. R. M., Chatterjee, N. A., Saour, B., Nguyen, D. D., Starnes, E., Johnston, C., Green, M. L., Roth, G. A., & Poole, J. E. (2020) · Heart Rhythm O2 · doi:10.1016/j.hroo.2020.06.002 · Cited by 15
Repurposing Drugs for the Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19)
Lovato, E. C. W., Barboza, L. N., Wietzikoski, S., de Souza, A. N. V., Auth, P. A., Gasparotto, A., & Lívero, F. A. D. R. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200707121636 · Cited by 15
Hydroxychloroquine use in hospitalised patients with COVID-19: An observational matched cohort study
Kalligeros, M., Shehadeh, F., Atalla, E., Mylona, E. K., Aung, S., Pandita, A., Larkin, J., Sanchez, M. C., Touzard-Romo, F., Brotherton, A. L., et al. (2020) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2020.07.018 · Cited by 15
Icosapent Ethyl – A Successful Treatment for Symptomatic COVID-19 Infection
Berger, A. A., Sherburne, R., Urits, I., Patel, H., & Eskander, J. P. (2020) · Cureus · doi:10.7759/cureus.10211 · Cited by 15
The Decline of the Experimental Paradigm During the COVID-19 Pandemic: A Template for the Future
Ferreira, J. P., Epstein, M., & Zannad, F. M. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.08.021 · Cited by 15
Safety of intravenous anakinra in COVID-19 with evidence of hyperinflammation, a case series
Clark, K. E. N., Collas, O., Lachmann, H. J., Singh, A., Buckley, J., & Bhagani, S. (2020) · Rheumatology Advances in Practice · doi:10.1093/rap/rkaa040 · Cited by 15
Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia
Mori, N., Katayama, M., & Nukaga, S. (2020) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2020.09.003 · Cited by 15
Acute aortoiliac occlusion in a patient with novel coronavirus disease-2019
Naudin, I., Long, A., Michel, C., Dévigne, B., Millon, A., & Della-Schiava, N. (2020) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2020.10.018 · Cited by 15
A 61-Year-Old Man with SARS-CoV-2 Infection and Venous Thrombosis Presenting with Painful Swelling and Gangrene of the Lower Limb Consistent with Phlegmasia Cerulea Dolens
Bamgboje, A. O., Hong, S., Mushiyev, S., & Pekler, G. (2020) · American Journal of Case Reports · doi:10.12659/ajcr.928342 · Cited by 15
Clinical course of COVID-19 disease in immunosuppressed renal transplant patients
Dheir, H., Sipahi, S., Yaylacı, S., ÇETİN, E. S., Genç, A. B., Fırat, N., Köroğlu, M., MURATDAĞI, G., Tomak, Y., Süner, K. Ö., et al. (2020) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-2007-260 · Cited by 15
Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH)
Dı́az, E., Menéndez, R. A., Cortés, P. V., Escapa, M. G., Suberviola, B., Lázaro, A. S., Marcos-Neira, P., Quintana‐Díaz, M., & González, M. C. (2021) · Medicina Intensiva (English Edition) · doi:10.1016/j.medine.2020.06.007 · Cited by 15
COVID-19 and cardiovascular disease
Suri, P., & Arora, V. M. (2020) · Journal of Medical and Scientific Research · doi:10.17727/jmsr.2020/8s1-8 · Cited by 15
Personalized prescription of ACEI/ARBs for hypertensive COVID-19 patients
Bertsimas, D., Borenstein, A., Mingardi, L., Nohadani, O., Orfanoudaki, A., Stellato, B., Wiberg, H., Sarin, P., Varelmann, D. J., Estrada, V., et al. (2021) · Health Care Management Science · doi:10.1007/s10729-021-09545-5 · Cited by 15
Immunogenicity and Neutralizing Activity Comparison of SARS-CoV-2 Spike Full-Length and Subunit Domain Proteins in Young Adult and Old-Aged Mice
Kim, K., Bhatnagar, N., Jeeva, S., Oh, J., Park, B. R., Shin, C. H., Wang, B., & Kang, S. (2021) · Vaccines · doi:10.3390/vaccines9040316 · Cited by 15
Drugs for the prevention and treatment of COVID-19 and its complications: An update on what we learned in the past 2 years
Remuzzi, G., Schiaffino, S., Santoro, M. G., FitzGerald, G. A., Melino, G., & Patrono, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.987816 · Cited by 16
Empfehlungen zur intensivmedizinischen Therapie von Patienten mit COVID-19 – 3. Version
Kluge, S., Janssens, U., Welte, T., Weber‐Carstens, S., Schälte, G., Salzberger, B., Gastmeier, P., Länger, F. P., Wepler, M., Westhoff, M., et al. (2020) · Der Pneumologe · doi:10.1007/s10405-020-00359-w · Cited by 15
Impact of repurposed drugs on the symptomatic COVID-19 patients
Hussain, I., Hussain, A., Alajmi, M. F., Rehman, M. T., & Amir, S. (2020) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2020.11.009 · Cited by 15
Renin-Angiotensin-Aldosterone System Inhibitors in COVID-19: A Review
Ferrari, F., Martins, V. M., Fuchs, F. D., & Stein, R. (2021) · Clinics · doi:10.6061/clinics/2021/e2342 · Cited by 15
COVID-19 ARDS
Sasidharan, S., Singh, V. A., Singh, J., Madan, G. S., Dhillon, H. S., Dash, P. K., Shibu, B., & Dhillon, G. K. (2021) · Journal of Anaesthesiology Clinical Pharmacology · doi:10.4103/joacp.joacp_14_21 · Cited by 15
Lack of efficacy of hydroxychloroquine in covid-19
Vinetz, J. M. (2020) · BMJ · doi:10.1136/bmj.m2018 · Cited by 15
COVID-19 treatments, QT interval, and arrhythmic risk: The need for an international registry on arrhythmias
Crotti, L., & Arbelo, E. (2020) · Heart Rhythm · doi:10.1016/j.hrthm.2020.05.024 · Cited by 15
Role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients
Favalli, E. G., Lucia, O. D., Biggioggero, M., Papa, N. D., & Caporali, R. F. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-218068 · Cited by 15
Treatment with COLchicine in hospitalized patients affected by COVID-19: The COLVID-19 trial
Perricone, C., Scarsi, M., Brucato, A. L., Pisano, P., Pigatto, E., Becattini, C., Cingolani, A., Tiso, F., Prota, R., Tomasoni, L. R., et al. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2022.10.016 · Cited by 14
Virtual and In Vitro Screening of Natural Products Identifies Indole and Benzene Derivatives as Inhibitors of SARS-CoV-2 Main Protease (Mpro)
Ang, D., Kendall, R., & Atamian, H. S. (2023) · Biology · doi:10.3390/biology12040519 · Cited by 14
Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis
Singer, M. E., Kaelber, D. C., & Antonelli, M. J. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-218500 · Cited by 14
Cytomegalovirus Enterocolitis secondary to experimental COVID-19 therapy
Geisen, W. R., Berger, J., Schwartz, C., Reddy, A., Rai, B., Wadih, G., & Peck, J. (2020) · IDCases · doi:10.1016/j.idcr.2020.e00962 · Cited by 14
Pharmacist’s Role and Pharmaceutical Care During the COVID-19 Pandemic
Amariles, P., Ledezma-Morales, M., Salazar-Ospina, A., & Hincapié-García, J. A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-63761-3_33 · Cited by 14
Association of Clinical and Immunological Characteristics With Disease Severity and Outcomes in 211 Patients With COVID-19 in Wuhan, China
Wang, M., Fan, Y., Chai, Y., Cheng, W., Wang, K., Cao, J., & Hu, X. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.667487 · Cited by 14
Off‐Label Use of Hydroxychloroquine in COVID‐19: Analysis of Reports of Suspected Adverse Reactions From the Italian National Network of Pharmacovigilance
Fallani, E., Cevenini, F., Lazzerini, P. E., Verdini, A., & Saponara, S. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2006 · Cited by 14
Synergistic Adverse Effects of Azithromycin and Hydroxychloroquine on Human Cardiomyocytes at a Clinically Relevant Treatment Duration
Li, W., Luo, X., Poetsch, M. S., Oertel, R., Nichani, K., Schneider, M., Strano, A., Hasse, M., Steiner, R.-P., Cyganek, L., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15020220 · Cited by 14
Role of traditional knowledge in the COVID‐19 battle
Ola, K. (2020) · The Journal of World Intellectual Property · doi:10.1111/jwip.12220 · Cited by 14
The Use of Meta‐analysis in Pharmacoepidemiology
Berlin, J. A. (2000) · Pharmacoepidemiology · doi:10.1002/0470842555.ch38 · Cited by 14
Hydroxychloroquine and COVID-19 – A narrative review
Bajpai, J., Pradhan, A. K., Singh, A., & Kant, S. (2020) · Indian Journal of Tuberculosis · doi:10.1016/j.ijtb.2020.06.004 · Cited by 14
Myotonic dystrophy type 1 as a major risk factor for severe COVID-19?
Dhont, S., Callens, R., Stevens, D., Bauters, F. A., Bleecker, J. D., Derom, E., & Braeckel, E. V. (2020) · Acta Neurologica Belgica · doi:10.1007/s13760-020-01514-z · Cited by 14
Chloroquine and hydroxychloroquine provoke arrhythmias at concentrations higher than those clinically used to treat COVID‐19: A simulation study
Okada, J., Yoshinaga, T., Washio, T., Sawada, K., Sugiura, S., & Hisada, T. (2021) · Clinical and Translational Science · doi:10.1111/cts.12976 · Cited by 14
COVID-19 Cardiovascular Connection: A Review of Cardiac Manifestations in COVID-19 Infection and Treatment Modalities
Maitz, T., Parfianowicz, D., VOJTEK, A., Rajeswaran, Y., Vyas, A. V., & Gupta, R. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101186 · Cited by 14
Hydroxychloroquine/chloroquine for the treatment of hospitalized patients with COVID-19: An individual participant data meta-analysis
Stefano, L. D., Ogburn, E. L., Ram, M., Scharfstein, D. O., Li, T., Khanal, P., Baksh, S. N., McBee, N. A., Gruber, J. B., Gildea, M. R., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0273526 · Cited by 14
The competing risk between in-hospital mortality and recovery: A pitfall in COVID-19 survival analysis researchPreprint
Oulhaj, A., Ahmed, L. A., Prattes, J., Suliman, A., Alsuwaidi, A. R., Al‐Rifai, R. H., Sourij, H., & Keilegom, I. V. (2020) · medRxiv · doi:10.1101/2020.07.11.20151472 · Cited by 14
Effectiveness of hydroxychloroquine in COVID-19 disease: A done and dusted deal?
Monforte, A. D., Tavelli, A., Bai, F., Marchetti, G. C., & Cozzi‐Lepri, A. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.07.056 · Cited by 14
Public Health Messaging on Twitter During the COVID-19 Pandemic: Observational Study
Rao, A., Sabri, N., Guo, S., Raschid, L., & Lerman, K. (2024) · Journal of Medical Internet Research · doi:10.2196/63910 · Cited by 13
COVID-19: A Perspective from Clinical Neurology and Neuroscience
Pero, A., Ng, S., & Cai, D. (2020) · The Neuroscientist · doi:10.1177/1073858420946749 · Cited by 13
COVID-19, neutrophil extracellular traps and vascular complications in obstetric practice
Makatsariya, A. D., Викторовна, С. Е., Bitsadze, V. O., Khizroeva, J. K., Tretyakova, M. V., Tsibizova, V. I., Dobryakov, A. B., Elalamy, I., & Gris, J. (2020) · Journal of Perinatal Medicine · doi:10.1515/jpm-2020-0280 · Cited by 13
Understanding immunopathological fallout of human coronavirus infections including COVID‐19: Will they cross the path of rheumatologists?
Kabeerdoss, J., & Danda, D. (2020) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.13909 · Cited by 13
How achievable are COVID-19 clinical trial recruitment targets? A UK observational cohort study and trials registry analysis
Cunniffe, N. G., Gunter, S. J., Brown, M., Burge, S., Coyle, C., Soyza, A. D., Dymond, T., Esmail, H., Francis, D. P., Galloway, J., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-044566 · Cited by 13
Comparing the impact of Hydroxychloroquine based regimens and standard treatment on COVID-19 patient outcomes: A retrospective cohort study
Almazrou, S. H., Almalki, Z. S., Alanazi, A. S., Alqahtani, A., & Alghamd, S. M. (2020) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2020.09.019 · Cited by 13
Establishment of a Collection of Blood-Derived Products from COVID-19 Patients for Translational Research: Experience of the LPCE Biobank (Nice, France)
Tanga, V., Leroy, S., Fayada, J., Hamila, M., Allégra, M., Messaoudi, Z., Bonnetaud, C., Lespinet, V., Bordone, O., Washetine, K., et al. (2020) · Biopreservation and Biobanking · doi:10.1089/bio.2020.0055 · Cited by 13
NRITLD Protocol for the Management of Patients with COVID-19 Admitted to Hospitals.
Marjani, M., Tabarsi, P., Moniri, A., Hashemian, S. M. R., Nadji, S. A., Abtahian, Z., Malekmohammad, M., Kiani, A., Farzanegan, B., Eslaminejad, A., et al. (2020) · PubMed Central · Cited by 13
Modalities and Mechanisms of Treatment for Coronavirus Disease 2019
Zuo, Z., Wu, T., Pan, L., Zuo, C., Hu, Y., Luo, X., Jiang, L., Xia, Z., Xiao, X., Liu, J., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.583914 · Cited by 14
SARS-CoV 2 Infection (Covid-19) and Cardiovascular Disease in Africa: Health Care and Socio-Economic Implications
Ogah, O. S., Umuerri, E. M., Adebiyi, A. A., Orimolade, O. A., Sani, M. U., Ojji, D. B., Mbakwem, A. C., Stewart, S., & Sliwa, K. S. (2021) · Global Heart · doi:10.5334/gh.829 · Cited by 13
Does hydroxychloroquine still have any role in the COVID-19 pandemic?
Schilling, W. H., & White, N. J. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1898589 · Cited by 13
Comparative incidence and outcomes of COVID‐19 in kidney or kidney‐pancreas transplant recipients versus kidney or kidney‐pancreas waitlisted patients: A single‐center study
Santos, C. A. Q., Rhee, Y., Hollinger, E. F., Olaitan, O. K., Schadde, E., Peev, V., Saltzberg, S. N., & Hertl, M. (2021) · Clinical Transplantation · doi:10.1111/ctr.14362 · Cited by 13
Risk communication in the fight against COVID-19 in Brazil: A rhetorical analysis
Silva, C. R. D. V., Bay, O. D. G., Martiniano, C. S., & Uchôa, S. A. D. C. (2021) · Physis Revista de Saúde Coletiva · doi:10.1590/s0103-73312021310204 · Cited by 13
Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine
Shirzad, M., Nourigorji, M., Sajedi, A., Ranjbar, M., Rasti, F., Sourani, Z., Moradi, M., Mir, S. M., & Memar, M. Y. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109161 · Cited by 13
Looking for SARS-CoV-2 Therapeutics Through Computational Approaches
Vincenzi, M., Mercurio, F. A., & Leone, M. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666221004104430 · Cited by 13
Data Imputation of Soil Pressure on Shield Tunnel Lining Based on Random Forest Model
Wang, M., Ye, X., Ying, X.-H., Jia, J.-D., Ding, Y., Zhang, D., & Sun, F. (2024) · Sensors · doi:10.3390/s24051560 · Cited by 13
SARS-COV-2 in Ophthalmology: Current Evidence and Standards for Clinical Practice
Torres-Costa, S., Lima-Fontes, M., Falcão‐Reis, F., & Falcão, M. S. (2020) · Acta Médica Portuguesa · doi:10.20344/amp.14118 · Cited by 13
Clinical Experience with Use of Remdesivir in the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2: a Case Series
Lee, C., Ahn, M. Y., Byeon, K., Choi, J., Hahm, C., Kim, H., Kim, S., Kim, T. H., Oh, J., & Oh, D. H. (2020) · Infection and Chemotherapy · doi:10.3947/ic.2020.52.3.369 · Cited by 13
Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization
Thémans, P., Belkhir, L., Dauby, N., Yombi, J. C., Greef, J. D., Delongie, K.-A., Vandeputte, M., Nasreddine, R., Wittebole, X., Wuillaume, F., et al. (2020) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-020-00648-y · Cited by 13
Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection
Carafoli, E. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.09.128 · Cited by 13
QTc prolongation among hydroxychloroquine sulphate‐treated COVID‐19 patients: An observational study
Fteiha, B., Karameh, H., Kurd, R., Ziff‐Werman, B., Feldman, I., Bnaya, A., Einav, S., Orlev, A., & Ben‐Chetrit, E. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13767 · Cited by 13
Factors associated with clinical outcomes in patients with Coronavirus Disease 2019 in Guangzhou, China
Lei, C., Lin, W., Deng, X., Hu, F., Chen, F., Cai, W., Li, Y., Wen, C., Guan, Y., Wang, J., et al. (2020) · Journal of Clinical Virology · doi:10.1016/j.jcv.2020.104661 · Cited by 13
4-Aminoquinoline compounds from the Spanish flu to COVID-19
Bazotte, R. B., Hirabara, S. M., Serdan, T. D. A., Gritte, R. B., Souza‐Siqueira, T., Gorjão, R., Masi, L. N., Antunes, M. M., Cruzat, V. F., Pithon‐Curi, T. C., et al. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111138 · Cited by 13
Risk factors for the early development of septic shock in patients with severe COVID-19
Glybochko, P. V., Fomin, V. V., Moiseev, S. V., Avdeev, S. N., Yavorovskiy, A. G., Brovko, M., Umbetova, K., Алиев, В. А., Bulanova, E. L., Bondarenko, I. B., et al. (2020) · Terapevticheskii arkhiv · doi:10.26442/00403660.2020.11.000780 · Cited by 13
Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19
Zahr, N., Urien, S., Llopis, B., Pourcher, V., Paccoud, O., Bleibtreu, A., Mayaux, J., Gandjbakhch, E., Hékimian, G., Combes, A., et al. (2021) · Therapies · doi:10.1016/j.therap.2021.01.056 · Cited by 13
Development of a Physiologically Based Pharmacokinetic Model for Hydroxychloroquine and Its Application in Dose Optimization in Specific COVID-19 Patients
Zhang, M., Yao, X., Hou, Z., Guo, X., Tu, S., Lei, Z., Yu, Z., Liu, X., Cui, C., Chen, X., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.585021 · Cited by 13
A metaresearch study revealed susceptibility of Covid-19 treatment research to white hat bias: first, do no harm
Bellos, I. (2021) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2021.03.020 · Cited by 13
Hydroxychloroquine and Azithromycin Treatment of Hospitalized Patients Infected with SARS-CoV-2 in Senegal from March to October 2020
Taieb, F., Mbaye, K. D., Tall, B., Lakhe, N. A., Talla, C., Thioub, D., Ndoye, A. M., Kà, D., Gaye, A., Diallo, V. M.-P. C., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132954 · Cited by 13
Implementation of documented and written informed consent for clinical trials of communicable diseases: Lessons learned, barriers, solutions, future directions identified during the conduct of a COVID-19 clinical trial
Woods, P. A., Flynn, M., Monach, P. A., Visnaw, K., Schiller, S., Holmberg, E. F., Leatherman, S. M., Ferguson, R. E., & Branch‐Elliman, W. (2021) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2021.100804 · Cited by 13
Antiviral drugs arbidol and interferon alpha-1b contribute to reducing the severity of COVID-19 patients: a retrospective cohort study
Yin, P., Meng, J., Chen, J., Gao, J., Wang, D., Liu, S., Guo, Q., Zhu, M., Zhang, G., Liu, Y., et al. (2021) · Virology Journal · doi:10.1186/s12985-021-01617-w · Cited by 13
Characteristics of published/registered clinical trials on COVID-19 treatment: A systematic review
Asili, P., Mirahmad, M., Tabatabaei‐Malazy, O., Manayi, A., Haghighat, E., Mahdavi, M. R., & Larijani, B. A. (2021) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-021-00422-8 · Cited by 13
Attitudes towards influenza, and COVID-19 vaccines during the COVID-19 pandemic among a representative sample of the Jewish Israeli population
Maor‬‏, ‪., & Caspi, S. (2022) · PLoS ONE · doi:10.1371/journal.pone.0255495 · Cited by 13
Impact of home CPAP-treated obstructive sleep apnea on COVID-19 outcomes in hospitalized patients
Sampol, J., Sáez, M., Martí, S., Pallero, M., Barrecheguren, M., Ferrer, J., Sampol, G., for the Vall d’Hebron COVID-19 Working Group, Sampol, J., Miarons, M., et al. (2022) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.10016 · Cited by 13
COVID-19 and hydroxychloroquine: Is the wonder drug failing?
Paliani, U., & Cardona, A. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.06.002 · Cited by 13
Re: effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: author's response
Fiolet, T., Guihur, A., Rebeaud, M. E., Mulot, M., Peiffer‐Smadja, N., & Mahamat‐Saleh, Y. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.10.031 · Cited by 13
Association between Hydroxyzine Use and Reduced Mortality in Patients Hospitalized for Coronavirus Disease 2019: Results from a multicenter observational studyPreprint
Hoertel, N., Rico, M. S., Vernet, R., Beeker, N., Neuraz, A., Blanco, C., Olfson, M., Lemogne, C., Meneton, P., Daniel, C., et al. (2020) · medRxiv · doi:10.1101/2020.10.23.20154302 · Cited by 13
Chloroquine and hydroxychloroquine in the environment and aquatic organisms: a review
Ferreira, M. T., & Carvalho, C. D. S. (2023) · Ambiente e Agua - An Interdisciplinary Journal of Applied Science · doi:10.4136/ambi-agua.2880 · Cited by 12
Update for Anaesthetists on Clinical Features of COVID-19 Patients and Relevant Management
Preckel, B., Schultz, M. J., Vlaar, A. P. J., Hulst, A. H., Hermanides, J., de Jong, M. D., Schlack, W. S., Stevens, M. F., Weenink, R. P., & Hollmann, M. W. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051495 · Cited by 12
The epidemiological and clinical profile of COVID-19 in children: Moroccan experience of the Cheikh Khalifa University Center
Chekhlabi, N., Kettani, C. E., Haoudar, A., Bahlaoui, A., Mahi, M., Ettair, S., & Dini, N. (2020) · Pan African Medical Journal · doi:10.11604/pamj.supp.2020.35.2.23571 · Cited by 12
Chloroquine or Hydroxychloroquine for Management of Coronavirus Disease 2019
Schluenz, L., Ramos-Otero, G. P., & Nawarskas, J. J. (2020) · Cardiology in Review · doi:10.1097/crd.0000000000000329 · Cited by 12
Immunomodulatory-based therapy as a potential promising treatment strategy against severe COVID-19 patients: A systematic review
Razmi, M., Hashemi, F., Gheytanchi, E., Manshadi, M. D., Ghods, R., & Madjd, Z. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106942 · Cited by 12
Hydroxychloroquine in Hospitalized Patients with COVID‐19: Real‐World Experience Assessing Mortality
Annie, F., Sirbu, C., Frazier, K. R., Broce, M., & Lucas, B. D. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2467 · Cited by 12
COVID-19 and Acute Respiratory Distress Syndrome. Impact of corticosteroid treatment and predictors of poor outcome
Vidal, P., Carbajo, L. D. R., Olmo, J. N.-D., Prol‐Silva, E., Varela, A. I. T., Rodríguez-Vázquez, A., Rodríguez-Rodríguez, P., Díaz-López, M. D., Fernández‐Ugidos, P., & Pérez-Veloso, M. A. (2020) · Revista Española de Quimioterapia · doi:10.37201/req/091.2020 · Cited by 12
Influence of colchicine prescription in COVID-19-related hospital admissions: a survival analysis
Madrid-García, A., Pérez-Sancristóbal, I., Colomer, J. I., León, L., Jover, J. A., Fernández‐Gutiérrez, B., Abásolo, L., & Rodríguez‐Rodríguez, L. (2021) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x211002684 · Cited by 12
The Rise and Fall of Hydroxychloroquine and Chloroquine in COVID-19
Aljadeed, R. (2021) · Journal of Pharmacy Practice · doi:10.1177/0897190021997399 · Cited by 12
Cardiac manifestations in pediatric COVID-19
Capucho, A. T., Resende, P. L. S., Mascarenhas, D. A., da Silva, C. L. M. R., Sawamura, K. S. S., Menezes, C. R. B., Diniz, M. D. F. R., Lianza, A. C., de Carvalho, W. B., Silva, C. A., et al. (2021) · Clinics · doi:10.6061/clinics/2021/e3001 · Cited by 12
Consensus statement and recommendations on the treatment of COVID-19: 2021 update
Ko, H.-K., Yu, W.-K., Pan, S., Chen, W.-C., Yang, K.-Y., Lin, Y.-T., Wang, F.-D., Yang, M.-H., & Chen, Y.-M. (2021) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000617 · Cited by 12
An Update on Pharmacological Relevance and Chemical Synthesis of Natural Products and Derivatives with Anti SARS‐CoV‐2 Activity
Shagufta, S., & Ahmad, I. (2021) · ChemistrySelect · doi:10.1002/slct.202103301 · Cited by 12
Formação de educadores do campo nas IFES brasileiras: Desafios do ensino remoto em tempos de pandemia Covid-19
de Andrade, F. M. R., Nogueira, L. P. M., & Neves, L. D. C. (2022) · Education Policy Analysis Archives · doi:10.14507/epaa.30.6616 · Cited by 12
Hydroxychloroquine for treatment of non‐hospitalized adults with COVID ‐19: A meta‐analysis of individual participant data of randomized trials
Mitjà, J., Reis, G., Boulware, D. R., Spivak, A. M., Sarwar, A., Johnston, C., Webb, B. J., Hill, M. D., Smith, D. M., Kremsner, P. G., et al. (2023) · Clinical and Translational Science · doi:10.1111/cts.13468 · Cited by 12
Real-life Management Strategy of COVID-19 Patients in Bangladesh with No Death: An Observational and Cohort Study
Akbar, S. M., Huq, A. F., Rahman, M. F., Islam, M. A., Iqbal, S. A., Rahman, A., & Abdullah, S. A. H. M. (2020) · Euroasian Journal of Hepato-Gastroenterology · doi:10.5005/jp-journals-10018-1316 · Cited by 12
Medication therapy strategies for the coronavirus disease 2019 (COVID-19): recent progress and challenges
Yang, X., Liu, Y., Liu, Y., Yang, Q., Wu, X., Huang, X., Liu, H., Cai, W., & Ma, G. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1805315 · Cited by 12
Impact of Hydroxychloroquine on Antibody Responses to the SARS-CoV-2 Coronavirus
Santos, I. K. F. D. M., & Costa, C. H. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01739 · Cited by 12
A comprehensive strategy for the early treatment of COVID-19 with azithromycin/hydroxychloroquine and/or corticosteroids: Results of a retrospective observational study in the French overseas department of Réunion Island
Dubernet, A., Larsen, K., Masse, L., Allyn, J., Foch, E., Bruneau, L., Maillot, A., Lagrange-Xélot, M., Thomas, V., Jaffar‐Bandjee, M., et al. (2020) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2020.08.001 · Cited by 12
Can endolysosomal deacidification and inhibition of autophagy prevent severe COVID-19?
Morris, G., Athan, E., Walder, K. R., Bortolasci, C. C., O'Neil, A. E., Marx, W., Berk, M., Carvalho, A. F., Maes, M. H. J., & Puri, B. K. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118541 · Cited by 12
An overview of antiviral strategies for coronavirus 2 (SARS‐CoV‐2) infection with special reference to antimalarial drugs chloroquine and hydroxychloroquine
Dragojevic-Simic, V. M., Miljković, M. N., Stamenković, D., Vekić, B., Ratković, N., Simić, R., & Rančić, N. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13825 · Cited by 12
A 21st Century Evil: Immunopathology and New Therapies of COVID-19
Silva, T. F., Tomiotto‐Pellissier, F., Sanfelice, R. A., Gonçalves, M. D., Bortoleti, B. T. D. S., Detoni, M. B., Rodrigues, A. C. J., Carloto, A. C. M., Concato, V. M., Siqueira, E. D. S., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.562264 · Cited by 12
QTc-interval prolongation and increased risk of sudden cardiac death associated with hydroxychloroquine
Ahmadizar, F., Soroush, N., Ikram, M. A., Kors, J. A., Kavousi, M., & Stricker, B. H. C. (2020) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa118 · Cited by 12
Cross-sectional observational study of epidemiology of COVID-19 and clinical outcomes of hospitalised patients in North West London during March and April 2020
Rao, G. G., Allen, A., Papineni, P., Wang, L., Anderson, C. S., McGregor, A. C., Whittington, A., John, L., Harris, M., Hiles, S., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-044384 · Cited by 12
A review on role of nitrous oxide nanoparticles, potential vaccine targets, drug, health care and artificial intelligence to combat COVID-19
Manigandan, S., Praveenkumar, T. R., & Brindhadevi, K. (2021) · Applied Nanoscience · doi:10.1007/s13204-021-01935-z · Cited by 12

Authors: Geleris, J., Sun, Y., Platt, J., Zucker, J., Baldwin, M., Hripcsak, G., Labella, A., Manson, D. K., Kubin, C., Barr, R. G., Sobieszczyk, M. E., & Schluger, N. W.
Affiliations: Columbia University Irving Medical Center (US)
Corresponding author: Schluger, Neil W.
ORCID: Geleris, Joshua
Sun, Yifei
Platt, Jonathan
Zucker, Jason
Baldwin, Matthew
Hripcsak, George
Manson, Daniel K.
Kubin, Christine
Barr, R. Graham
Sobieszczyk, Magdalena E.
Schluger, Neil W.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2020-06-18
Volume: 382
Issue: 25
Pages: 2411-2418
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa2012410
PMC: PMC7224609
OpenAlex: W3023346879
Cited by: 1,625
References: 17
Citations by year: 2026: 16 · 2025: 23 · 2024: 57 · 2023: 80 · 2022: 167 · 2021: 440 · 2020: 839
FWCI: 49.99
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (RO1-HL077612, RO1-HL093081, RO1-HL121270, RO1-LM006910)
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (200-2009-32593)
Topics: Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Respiratory Support and Mechanisms
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Keywords: hydroxychloroquine, COVID-19 pandemic, mechanical ventilation, intubation, mortality, hospitalized patients, antimalarial drugs, treatment efficacy, propensity score weighting, SARS-CoV-2
MeSH terms: Betacoronavirus, COVID-19, SARS-CoV-2, COVID-19 Drug Treatment, Adult, Aged, Aged, 80 and over, Female, Hospitalization, Humans, Hydroxychloroquine, Intubation, Male, Middle Aged, New York City, Pneumonia, Viral, Treatment Failure, Coronavirus Infections, Propensity Score, Pandemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks